{"id":103,"date":"2011-02-15T20:54:41","date_gmt":"2011-02-15T20:54:41","guid":{"rendered":"https:\/\/blogs.bmj.com\/jmg\/?p=103"},"modified":"2026-02-22T00:40:03","modified_gmt":"2026-02-22T00:40:03","slug":"melanoma-risk-for-cdkn2a-mutation-carriers-who-are-relatives-of-population-based-case-carriers-in-australia-and-the-uk","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/jmg\/2011\/02\/15\/melanoma-risk-for-cdkn2a-mutation-carriers-who-are-relatives-of-population-based-case-carriers-in-australia-and-the-uk\/","title":{"rendered":"Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK (Contributed by Dr. Anne E Cust)"},"content":{"rendered":"

In this study conducted in Australia and the United Kingdom, we estimated that about 18% of people with a CDKN2A mutation would develop melanoma by the age of 50 years, and about 50% would develop melanoma by age 80 years. These lifetime risks are substantially higher than the risk of melanoma for the general population. Contrary to the known strong link between sunlight exposure and melanoma risk for the general population, people who carry a CDKN2A mutation appear to have the same lifetime risk of melanoma irrespective of the amount of sunlight to which they are exposed. (http:\/\/jmg.bmj.com\/content\/early\/2011\/02\/15\/jmg.2010.086538.abstract?papetoc<\/a>= )<\/p>\n","protected":false},"excerpt":{"rendered":"

In this study conducted in Australia and the United Kingdom, we estimated that about 18% of people with a CDKN2A mutation would develop melanoma by the age of 50 years, and about 50% would develop melanoma by age 80 years. These lifetime risks are substantially higher than the risk of melanoma for the general population. […]<\/p>\n

Read More…<\/a><\/p>\n","protected":false},"author":123,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-103","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"\nMelanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK (Contributed by Dr. Anne E Cust) - JMG Contact blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/jmg\/2011\/02\/15\/melanoma-risk-for-cdkn2a-mutation-carriers-who-are-relatives-of-population-based-case-carriers-in-australia-and-the-uk\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK (Contributed by Dr. Anne E Cust) - JMG Contact blog\" \/>\n<meta property=\"og:description\" content=\"In this study conducted in Australia and the United Kingdom, we estimated that about 18% of people with a CDKN2A mutation would develop melanoma by the age of 50 years, and about 50% would develop melanoma by age 80 years. These lifetime risks are substantially higher than the risk of melanoma for the general population. [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/jmg\/2011\/02\/15\/melanoma-risk-for-cdkn2a-mutation-carriers-who-are-relatives-of-population-based-case-carriers-in-australia-and-the-uk\/\" \/>\n<meta property=\"og:site_name\" content=\"JMG Contact blog\" \/>\n<meta property=\"article:published_time\" content=\"2011-02-15T20:54:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-22T00:40:03+00:00\" \/>\n<meta name=\"author\" content=\"hqqu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@HuiQiQu\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hqqu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2011\\\/02\\\/15\\\/melanoma-risk-for-cdkn2a-mutation-carriers-who-are-relatives-of-population-based-case-carriers-in-australia-and-the-uk\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2011\\\/02\\\/15\\\/melanoma-risk-for-cdkn2a-mutation-carriers-who-are-relatives-of-population-based-case-carriers-in-australia-and-the-uk\\\/\"},\"author\":{\"name\":\"hqqu\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\"},\"headline\":\"Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK (Contributed by Dr. Anne E Cust)\",\"datePublished\":\"2011-02-15T20:54:41+00:00\",\"dateModified\":\"2026-02-22T00:40:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2011\\\/02\\\/15\\\/melanoma-risk-for-cdkn2a-mutation-carriers-who-are-relatives-of-population-based-case-carriers-in-australia-and-the-uk\\\/\"},\"wordCount\":129,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2011\\\/02\\\/15\\\/melanoma-risk-for-cdkn2a-mutation-carriers-who-are-relatives-of-population-based-case-carriers-in-australia-and-the-uk\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2011\\\/02\\\/15\\\/melanoma-risk-for-cdkn2a-mutation-carriers-who-are-relatives-of-population-based-case-carriers-in-australia-and-the-uk\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2011\\\/02\\\/15\\\/melanoma-risk-for-cdkn2a-mutation-carriers-who-are-relatives-of-population-based-case-carriers-in-australia-and-the-uk\\\/\",\"name\":\"Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK (Contributed by Dr. Anne E Cust) - JMG Contact blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\"},\"datePublished\":\"2011-02-15T20:54:41+00:00\",\"dateModified\":\"2026-02-22T00:40:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2011\\\/02\\\/15\\\/melanoma-risk-for-cdkn2a-mutation-carriers-who-are-relatives-of-population-based-case-carriers-in-australia-and-the-uk\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2011\\\/02\\\/15\\\/melanoma-risk-for-cdkn2a-mutation-carriers-who-are-relatives-of-population-based-case-carriers-in-australia-and-the-uk\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2011\\\/02\\\/15\\\/melanoma-risk-for-cdkn2a-mutation-carriers-who-are-relatives-of-population-based-case-carriers-in-australia-and-the-uk\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK (Contributed by Dr. Anne E Cust)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"name\":\"JMG Contact blog\",\"description\":\"JMG Contact blog\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\",\"name\":\"JMG Contact blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"width\":300,\"height\":34,\"caption\":\"JMG Contact blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\",\"name\":\"hqqu\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"caption\":\"hqqu\"},\"description\":\"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.\",\"sameAs\":[\"https:\\\/\\\/x.com\\\/HuiQiQu\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/author\\\/hqiqu\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK (Contributed by Dr. Anne E Cust) - JMG Contact blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/jmg\/2011\/02\/15\/melanoma-risk-for-cdkn2a-mutation-carriers-who-are-relatives-of-population-based-case-carriers-in-australia-and-the-uk\/","og_locale":"en_US","og_type":"article","og_title":"Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK (Contributed by Dr. Anne E Cust) - JMG Contact blog","og_description":"In this study conducted in Australia and the United Kingdom, we estimated that about 18% of people with a CDKN2A mutation would develop melanoma by the age of 50 years, and about 50% would develop melanoma by age 80 years. These lifetime risks are substantially higher than the risk of melanoma for the general population. [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/jmg\/2011\/02\/15\/melanoma-risk-for-cdkn2a-mutation-carriers-who-are-relatives-of-population-based-case-carriers-in-australia-and-the-uk\/","og_site_name":"JMG Contact blog","article_published_time":"2011-02-15T20:54:41+00:00","article_modified_time":"2026-02-22T00:40:03+00:00","author":"hqqu","twitter_card":"summary_large_image","twitter_creator":"@HuiQiQu","twitter_misc":{"Written by":"hqqu","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/jmg\/2011\/02\/15\/melanoma-risk-for-cdkn2a-mutation-carriers-who-are-relatives-of-population-based-case-carriers-in-australia-and-the-uk\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2011\/02\/15\/melanoma-risk-for-cdkn2a-mutation-carriers-who-are-relatives-of-population-based-case-carriers-in-australia-and-the-uk\/"},"author":{"name":"hqqu","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b"},"headline":"Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK (Contributed by Dr. Anne E Cust)","datePublished":"2011-02-15T20:54:41+00:00","dateModified":"2026-02-22T00:40:03+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2011\/02\/15\/melanoma-risk-for-cdkn2a-mutation-carriers-who-are-relatives-of-population-based-case-carriers-in-australia-and-the-uk\/"},"wordCount":129,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/jmg\/2011\/02\/15\/melanoma-risk-for-cdkn2a-mutation-carriers-who-are-relatives-of-population-based-case-carriers-in-australia-and-the-uk\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/jmg\/2011\/02\/15\/melanoma-risk-for-cdkn2a-mutation-carriers-who-are-relatives-of-population-based-case-carriers-in-australia-and-the-uk\/","url":"https:\/\/blogs.bmj.com\/jmg\/2011\/02\/15\/melanoma-risk-for-cdkn2a-mutation-carriers-who-are-relatives-of-population-based-case-carriers-in-australia-and-the-uk\/","name":"Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK (Contributed by Dr. Anne E Cust) - JMG Contact blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#website"},"datePublished":"2011-02-15T20:54:41+00:00","dateModified":"2026-02-22T00:40:03+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2011\/02\/15\/melanoma-risk-for-cdkn2a-mutation-carriers-who-are-relatives-of-population-based-case-carriers-in-australia-and-the-uk\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/jmg\/2011\/02\/15\/melanoma-risk-for-cdkn2a-mutation-carriers-who-are-relatives-of-population-based-case-carriers-in-australia-and-the-uk\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/jmg\/2011\/02\/15\/melanoma-risk-for-cdkn2a-mutation-carriers-who-are-relatives-of-population-based-case-carriers-in-australia-and-the-uk\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/jmg\/"},{"@type":"ListItem","position":2,"name":"Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK (Contributed by Dr. Anne E Cust)"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/jmg\/#website","url":"https:\/\/blogs.bmj.com\/jmg\/","name":"JMG Contact blog","description":"JMG Contact blog","publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/jmg\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/jmg\/#organization","name":"JMG Contact blog","url":"https:\/\/blogs.bmj.com\/jmg\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","width":300,"height":34,"caption":"JMG Contact blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b","name":"hqqu","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","caption":"hqqu"},"description":"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.","sameAs":["https:\/\/x.com\/HuiQiQu"],"url":"https:\/\/blogs.bmj.com\/jmg\/author\/hqiqu\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/103","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/users\/123"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/comments?post=103"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/103\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/media?parent=103"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/categories?post=103"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/tags?post=103"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}